PTC Therapeutics (PTCT) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

PTC Therapeutics Revenue Highlights

Latest Revenue (Y)

$1.73B

Latest Revenue (Q)

$360.52M

Main Segment (Y)

Collaboration and License Revenue

Main Geography (Y)

Non-US

PTC Therapeutics Revenue by Period

PTC Therapeutics Revenue by Year

Date	Revenue	Change
2025-12-31	$1.73B	114.51%
2024-12-31	$806.78M	-13.97%
2023-12-31	$937.82M	34.20%
2022-12-31	$698.80M	29.75%
2021-12-31	$538.59M	41.45%
2020-12-31	$380.77M	24.04%
2019-12-31	$306.98M	15.96%
2018-12-31	$264.73M	36.19%
2017-12-31	$194.39M	135.04%
2016-12-31	$82.70M	124.95%
2015-12-31	$36.77M	60.11%
2014-12-31	$22.96M	-26.70%
2013-12-31	$31.33M	8.85%
2012-12-31	$28.78M	-70.92%
2011-12-31	$98.96M	-

PTC Therapeutics generated $1.73B in revenue during NA 2025, up 114.51% compared to the previous quarter, and up 454.52% compared to the same period a year ago.

PTC Therapeutics Revenue by Quarter

Date	Revenue	Change
2026-06-30	$360.52M	32.28%
2026-03-31	$272.55M	65.51%
2025-12-31	$164.68M	-21.96%
2025-09-30	$211.01M	17.96%
2025-06-30	$178.88M	-84.79%
2025-03-31	$1.18B	451.71%
2024-12-31	$213.17M	8.33%
2024-09-30	$196.79M	5.40%
2024-06-30	$186.70M	-11.14%
2024-03-31	$210.12M	-31.57%
2023-12-31	$307.06M	56.20%
2023-09-30	$196.58M	-8.06%
2023-06-30	$213.81M	-2.98%
2023-03-31	$220.38M	31.64%
2022-12-31	$167.41M	-22.90%
2022-09-30	$217.13M	31.17%
2022-06-30	$165.53M	11.29%
2022-03-31	$148.74M	-9.98%
2021-12-31	$165.23M	19.09%
2021-09-30	$138.74M	18.91%
2021-06-30	$116.68M	-1.07%
2021-03-31	$117.94M	-0.78%
2020-12-31	$118.86M	0.39%
2020-09-30	$118.40M	57.37%
2020-06-30	$75.24M	10.23%
2020-03-31	$68.26M	-29.24%
2019-12-31	$96.46M	35.07%
2019-09-30	$71.42M	-16.49%
2019-06-30	$85.52M	59.61%
2019-03-31	$53.58M	-37.94%
2018-12-31	$86.34M	61.11%
2018-09-30	$53.59M	-22.04%
2018-06-30	$68.74M	22.62%
2018-03-31	$56.06M	-28.15%
2017-12-31	$78.03M	86.44%
2017-09-30	$41.85M	-12.74%
2017-06-30	$47.96M	80.67%
2017-03-31	$26.55M	5.38%
2016-12-31	$25.19M	9.59%
2016-09-30	$22.99M	47.04%
2016-06-30	$15.63M	-17.26%
2016-03-31	$18.89M	24.17%
2015-12-31	$15.22M	55.69%
2015-09-30	$9.77M	53.49%
2015-06-30	$6.37M	17.77%
2015-03-31	$5.41M	-53.40%
2014-12-31	$11.60M	1355.71%
2014-09-30	$797.00K	-43.79%
2014-06-30	$1.42M	-84.50%
2014-03-31	$9.15M	132.70%
2013-12-31	$3.93M	-74.57%
2013-09-30	$15.46M	163.39%
2013-06-30	$5.87M	-3.37%
2013-03-31	$6.07M	2.60%
2012-12-31	$5.92M	-2.06%
2012-09-30	$6.04M	-0.36%
2012-06-30	$6.06M	-43.60%
2012-03-31	$10.75M	-

PTC Therapeutics generated $360.52M in revenue during Q2 2026, up 32.28% compared to the previous quarter, and up 30.65% compared to the same period a year ago.

PTC Therapeutics Revenue Breakdown

PTC Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 25	Dec 24	Dec 23	Dec 19	Dec 18
Royalty	$244.22M	$203.86M	-	-	-
Collaboration and License Revenue	$998.36M	-	-	-	-
Product	$586.70M	$600.95M	$291.31M	-	-
Collaboration Revenue	-	$304.00K	$100.03M	-	-
Manufacturing	-	$1.66M	$7.69M	-	-
Grant And Collaboration	-	-	-	$15.67M	-
Early Stage Collaborations	-	-	-	-	$252.00M
Licensing And Collaboration Agreement	-	-	-	-	$200.00K
Emflaza	-	-	-	-	$92.00M
Grant	-	-	-	-	-
Translarna	-	-	-	-	$171.00M

PTC Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 25: Collaboration and License Revenue (54.58%), Product (32.07%), and Royalty (13.35%).

Quarterly Revenue by Product

Product/Service	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Mar 24	Dec 23	Jun 23	Mar 23	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Royalty	$71.11M	$46.84M	$79.39M	$70.79M	$57.60M	$36.44M	$142.50M	$61.37M	$4.09M	$696.00K	-	-	-	-	-	-	-	-	-	-
Collaboration and License Revenue	$50.59M	$143.00K	-	$9.26M	$2.94M	$986.23M	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Product	$238.82M	$225.57M	$183.99M	$130.96M	$118.33M	$153.43M	$465.53M	$135.42M	$103.11M	$91.28M	$107.26M	$82.71M	$75.24M	$68.20M	$81.41M	$71.37M	-	-	-	-
Manufacturing	-	-	-	-	-	-	-	$800.00K	$1.36M	$3.34M	$2.36M	$1.99M	-	-	-	-	-	-	-	-
Net product revenue	-	-	-	-	-	-	-	-	$177.60M	-	-	-	-	-	-	-	-	-	-	-
Grant And Collaboration	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$7.52M	$35.00M	-	$63.00K	$15.05M	$47.00K

PTC Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Jun 26: Product (66.24%), Royalty (19.72%), and Collaboration and License Revenue (14.03%).

PTC Therapeutics Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Non-US	$334.52M	$393.80M	$406.16M	$288.60M	$236.00M
UNITED STATES	$252.19M	$413.04M	-	-	-
United States	-	$413.04M	$531.66M	$218.30M	$187.30M

PTC Therapeutics's latest annual revenue breakdown by geography, as of Dec 25: Non-US (57.02%), and UNITED STATES (42.98%).

Quarterly Revenue by Country

Country	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Dec 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
Non-US	$86.64M	$89.06M	$178.01M	$74.53M	$81.98M	$117.96M	$96.50M	$115.10M	$55.70M	$76.60M	$77.00M	$79.20M	$69.70M	-
UNITED STATES	$152.18M	$136.52M	$159.41M	$56.42M	$36.35M	-	-	-	-	-	-	-	-	-
United States	-	-	-	-	$36.35M	$343.96M	$65.70M	$54.60M	$58.20M	$54.80M	$56.80M	$48.60M	$47.50M	-
BRAZIL	-	-	-	-	$40.95M	-	-	-	-	-	-	-	-	-
Non Us	-	-	-	-	-	-	-	-	-	-	-	-	-	$67.20M
U	-	-	-	-	-	-	-	-	-	-	-	-	-	$47.10M

PTC Therapeutics's latest quarterly revenue breakdown by geography, as of Jun 26: UNITED STATES (63.72%), and Non-US (36.28%).

PTC Therapeutics Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
PTCT	PTC Therapeutics	$1.73B	$360.52M
ALKS	Alkermes	$1.48B	$496.01M
ARWR	Arrowhead Pharmaceuticals	$829.45M	$75.25M
TGTX	TG Therapeutics	$616.29M	$240.34M
KRYS	Krystal Biotech	$389.13M	$119.22M
RNA	Atrium Therapeutics	$18.75M	$12.47M
CRNX	Crinetics Pharmaceuticals	$5.42M	$25.12M
PTGX	Protagonist Therapeutics	-	-
PCVX	Vaxcyte	-	-
MTSR	Metsera	-	-

PTCT Revenue FAQ

What is PTC Therapeutics’s yearly revenue?

PTC Therapeutics's yearly revenue for 2025 was $1.73B, representing an increase of 114.51% compared to 2024. The company's yearly revenue for 2024 was $806.78M, representing a decrease of -13.97% compared to 2023. PTCT's yearly revenue for 2023 was $937.82M, representing an increase of 34.20% compared to 2022.

What is PTC Therapeutics’s quarterly revenue?

PTC Therapeutics's quarterly revenue for Q2 2026 was $360.52M, a 32.28% increase from the previous quarter (Q1 2026), and a 101.55% increase year-over-year (Q2 2025). The company's quarterly revenue for Q1 2026 was $272.55M, a 65.51% increase from the previous quarter (Q4 2025), and a -76.83% decrease year-over-year (Q1 2025). PTCT's quarterly revenue for Q4 2025 was $164.68M, a -21.96% decrease from the previous quarter (Q3 2025), and a -22.75% decrease year-over-year (Q4 2024).

What is PTC Therapeutics’s revenue growth rate?

PTC Therapeutics's revenue growth rate for the last 3 years (2023-2025) was 84.54%, and for the last 5 years (2021-2025) was 221.33%.

What are PTC Therapeutics’s revenue streams?

PTC Therapeutics's revenue streams in c 25 are Royalty, Collaboration and License Revenue, and Product. Royalty generated $244.22M in revenue, accounting 13.35% of the company's total revenue, up 19.80% year-over-year. Collaboration and License Revenue generated $998.36M in revenue, accounting 54.58% of the company's total revenue Product generated $586.7M in revenue, accounting 32.07% of the company's total revenue, down -2.37% year-over-year.

What is PTC Therapeutics’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of PTC Therapeutics was Collaboration and License Revenue. This segment made a revenue of $998.36M, representing 54.58% of the company's total revenue.